Taipei, Taiwan, January 2, 2019 / PRNewswire / – APRINOIA Therapeutics, a clinical-stage biotechnology company developing drugs and diagnostic tools for neurodegenerative diseases, announced today that it has entered into a non-exclusive license agreement with Celgene Corporation. The agreement allows Celgene to use APN-1607, a new investigation[[[[18F]-labeled positron emission tomography (PET) imaging tracer to support patient selection and evaluation of efficacy in its worldwide clinical trials. According to the agreement, APRINOIA receives non-disclosed annual license and operating costs.
APN-1607 has been clinically evaluated in several countries / regions, including the United States, Japan, Taiwanand mainland of China. It is a PET imaging tracer with the potential to visualize tau pathology in various tauopathies, including mild cognitive impairment (MCI), dementia due to Alzheimer's disease (AD), Corticobasal degeneration syndrome (CBS) and Progressive Supranuclear Palsy (PSP). Specifically for PSP, APRINOIA received the FDA Orphan Drug Designation status for APN-1607 in this indication in 2017.
APRINOIA is currently implementing APN-1607 globally in leading academic medical centers to provide employees with access to technology. Her partners can use APN-1607 to better understand the natural history of tau pathology in rare tauopathies and Alzheimer's disease. APN-1607 also has important value in the development of effective treatments for these diseases. APRINOIA uses this tracer to stimulate its own tau therapeutic program.
"We are excited to partner with Celgene, one of our most valued global partners," said Ming-Kuei Jang, PhD, CEO OF APRINOIA. "With the unique properties of APN-1607, we believe that it can provide our partners with a valuable tool to validate therapeutic candidates for various neurodegenerative diseases, including multiple tauopathies."
More information about APRINOIA Therapeutics and its technology can be found on its website.
About APRINOIA Therapeutics Inc.
APRINOIA Therapeutics, with headquarters in Taipei, Taiwan, is a biotechnology company in the clinical phase that develops therapeutic and diagnostic imaging tools for neurodegenerative diseases. APRINOIA is currently promoting a pipeline with three diagnostic and two therapeutic products, which focus on brain disorders related to tau and alpha-synuclein, while the next wave of therapeutic projects is being incubated.
The company strives for a strong pipeline with innovative products and also builds strong partnerships with global and regional pharmaceutical companies to accelerate product development. The company currently has activities in it Taiwan, Mainland China, and Japan.
For more information, go to:
SOURCE APRINOIA Therapeutics Inc.